Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells

被引:8
|
作者
Jugova, Alzbeta [1 ]
Sustackova, Gabriela [1 ]
Legartova, Sona [1 ]
Stixova, Lenka [1 ]
Kozubek, Stanislav [1 ]
Bartova, Eva [1 ]
机构
[1] Acad Sci Czech Republ, Inst Biophys, Vvi, CZ-61265 Brno, Czech Republic
关键词
epigenetics; histone code; leukaemia cells; multiple myeloma (MM); GENE-EXPRESSION; DNA METHYLATION; HP1; PROTEINS; CANCER; HETEROCHROMATIN; HP1(HS-ALPHA); INHIBITION; RECEPTOR; TARGETS;
D O I
10.1042/CBI20100820
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Here, we focus on epigenetic changes in leukaemia and MM (multiple myeloma) cells. We show how the histone signature, DNA methylation and levels of select tumour-suppressor proteins can be affected by inhibitors of HDACs (histone deacetylases) and Dnmts (DNA methyltransferases). Both inhibitors, TSA (trichostatin A) and 5-AZA (5-azacytidine), have the ability to change the histone signature in a tumour-specific manner. In MM cells, we observed changes in H3K4 methylation, while in leukaemia cells, H3K9 methylation was especially affected by select inhibitors. Compared with normal peripheral blood lymphocytes, tumour cell samples were characterized by increased H3K9 acetylation, increased H3K4me2, H3K9me2 and HP1 alpha (heterochromatin protein 1 alpha) levels and specific changes were also observed for DNA methylation. Additionally, we showed that the tumour suppressor pRb1 (retinoblastoma protein) is more sensitive to epigenetic-based anti-cancer stimuli than p53. We have found significant decrease in the levels of pRbl and p53 in both myeloma and leukaemia cells after HDAC inhibition.
引用
收藏
页码:1195 / 1203
页数:9
相关论文
共 50 条
  • [31] METABOLISM OF ANTI-CANCER DRUGS
    CONNORS, TA
    BIOCHIMIE, 1978, 60 (09) : 1070 - 1070
  • [32] Anti-cancer drugs - Preface
    Bergmann-Leitner, E
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (25)
  • [33] Anti-cancer drugs for thyroid cancer
    Tahara, Makoto
    ANNALS OF ONCOLOGY, 2017, 28 : 63 - 63
  • [34] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS FOR ANTI-CANCER DRUGS
    CHEN, HSG
    GROSS, JF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 2 (02) : 85 - 94
  • [35] Anti-Cancer Effects of Epigenetics Drugs Scriptaid and Zebularine in Human Breast Adenocarcinoma Cells
    Yap, Zhi Hung
    Kong, Wei Yang
    Azeez, Abdur Rahmaan
    Fang, Chee-Mun
    Ngai, Siew Ching
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (08) : 1582 - 1590
  • [36] Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation
    Mastrangelo, Domenico
    Pelosi, Elvira
    Castelli, Germana
    Lo-Coco, Francesco
    Testa, Ugo
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 69 : 57 - 64
  • [37] Quantitative parabolic optimization platform for the design of epigenetic-based drug combinations against bortezomib-resistant multiple myeloma
    Chow, Edward Kai-Hua
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [38] Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin
    Zhang, Li
    Wang, Handong
    MARINE DRUGS, 2015, 13 (07): : 4310 - 4330
  • [39] Electronic polarization effects on membrane translocation of anti-cancer drugs
    Hosseini, Atiyeh
    Lund, Mikael
    Ejtehadi, Mohammad Reza
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2022, 24 (20) : 12281 - 12292
  • [40] Epigenetic-based therapy for colorectal cancer: Prospect and involved mechanisms
    Rezapour, Saleheh
    Hosseinzadeh, Elham
    Marofi, Faroogh
    Hassanzadeh, Ali
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (11) : 19366 - 19383